| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 557.64% | Oppenheimer | → $34 | Reiterates | Outperform → Outperform |
| 06/27/2023 | 190.14% | Cantor Fitzgerald | → $15 | Reiterates | Overweight → Overweight |
| 06/13/2023 | 557.64% | Oppenheimer | $37 → $34 | Maintains | Outperform |
| 03/28/2023 | 190.14% | Cantor Fitzgerald | $3 → $15 | Maintains | Overweight |
| 05/13/2022 | -22.63% | Barclays | $6 → $4 | Maintains | Overweight |
| 04/01/2022 | — | SMBC Nikko | Downgrades | Outperform → Neutral | |
| 03/31/2022 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 11/16/2021 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 11/05/2021 | 151.45% | Oppenheimer | $15 → $13 | Maintains | Outperform |
| 08/18/2021 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 03/02/2021 | 190.14% | JP Morgan | $14 → $15 | Assumes | → Overweight |
| 01/07/2021 | 209.48% | Cantor Fitzgerald | → $16 | Initiates Coverage On | → Overweight |
| 04/01/2020 | 441.59% | Oppenheimer | $29 → $28 | Maintains | Outperform |
| 09/17/2019 | 499.61% | Guggenheim | → $31 | Initiates Coverage On | → Buy |
| 09/05/2019 | 306.19% | Barclays | → $21 | Initiates Coverage On | → Overweight |
| 08/30/2019 | 402.9% | Oppenheimer | → $26 | Initiates Coverage On | → Outperform |
| 12/17/2018 | 306.19% | Goldman Sachs | $18 → $21 | Upgrades | Neutral → Buy |
| 11/26/2018 | 422.24% | Cowen & Co. | → $27 | Initiates Coverage On | → Outperform |
| 11/26/2018 | 248.16% | Goldman Sachs | → $18 | Initiates Coverage On | → Neutral |
| 11/26/2018 | 383.56% | Wedbush | → $25 | Initiates Coverage On | → Outperform |
| 11/26/2018 | — | JP Morgan | Initiates Coverage On | → Overweight |
What is the target price for Orchard Therapeutics (ORTX)?
The latest price target for Orchard Therapeutics (NASDAQ: ORTX) was reported by Oppenheimer on August 9, 2023. The analyst firm set a price target for $34.00 expecting ORTX to rise to within 12 months (a possible 557.64% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Orchard Therapeutics (ORTX)?
The latest analyst rating for Orchard Therapeutics (NASDAQ: ORTX) was provided by Oppenheimer, and Orchard Therapeutics reiterated their outperform rating.
When is the next analyst rating going to be posted or updated for Orchard Therapeutics (ORTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Orchard Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Orchard Therapeutics was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
Is the Analyst Rating Orchard Therapeutics (ORTX) correct?
While ratings are subjective and will change, the latest Orchard Therapeutics (ORTX) rating was a reiterated with a price target of $0.00 to $34.00. The current price Orchard Therapeutics (ORTX) is trading at is $5.17, which is within the analyst's predicted range.